Journal of Nuclear Cardiology

, Volume 20, Issue 2, pp 284–288

Regadenoson: A focused update

Authors

  • Gopal Ghimire
    • Division of Cardiovascular DiseasesUniversity of Alabama at Birmingham
    • Division of Cardiovascular DiseasesUniversity of Alabama at Birmingham
    • Section of CardiologyBirmingham Veteran’s Administration Medical Center
  • Jaekyeong Heo
    • Division of Cardiovascular DiseasesUniversity of Alabama at Birmingham
  • Ami E. Iskandrian
    • Division of Cardiovascular DiseasesUniversity of Alabama at Birmingham
Review Article

DOI: 10.1007/s12350-012-9661-3

Cite this article as:
Ghimire, G., Hage, F.G., Heo, J. et al. J. Nucl. Cardiol. (2013) 20: 284. doi:10.1007/s12350-012-9661-3

Abstract

Since its approval by the Food and Drug Administration in 2008, regadenoson has become the most commonly used vasodilator in the United States. Previous reviews have summarized the pre-clinical and clinical data on the use of regadenoson for myocardial perfusion imaging (MPI). Since then, data have emerged on the safety of this agent in special groups of patients such as those with chronic kidney disease, airway disease (asthma and chronic obstructive pulmonary disease), and liver disease. There has also been recent interest in the use of regadenoson in hybrid protocols with exercise as a way to improve patient tolerance and image quality. Finally, although regadenoson was approved for clinical use based on the agreement rate of regadenoson MPI and adenosine MPI with regards to perfusion abnormalities, data are now available on the prognostic data derived from regadenoson MPI. We will briefly summarize these recent reports here in a focused update on the use of regadenoson for MPI.

Keywords

Regadenosonpharmacological stress testingadenosineSPECT

Copyright information

© American Society of Nuclear Cardiology 2012